ACTG 359:SOFT GELATIN CAPSULE OF SAQUINAVIR W/ RITONAVIR OR NELFINAVI

ACTG 359：沙奎那韦软明胶胶囊含利托那韦或奈非那韦

• 批准号: 6264446
• 负责人: ROBERT KALAYJIAN
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264446
• 关键词: AIDS therapy; antiAIDS agent; clinical research; combination chemotherapy; delavirdine; human subject; human therapy evaluation; protease inhibitor; ritonavir; saquinavir

CORE LAB ONLY - SAMPLE PROCESSING. The HIV protease inhibitors are a new class of antiretroviral agents with potent activity. Indinavir, given to zidovudine-experienced patients in combination with zidovudine and lamivudine, reduced viral loads in about 85% of patients to less than 500 copies per milliliter for up to one year. This leaves at least 15% of patients who continue to have viral loads above 500 copies per milliliter despite the indinavir-containing combination regimen. The optimal therapy for a person on an indinavir-containing combination regimen whose experiences are abound in viral load or never experiences a decrease in viral load below 500 copies per milliliter is unknown. This study formally tests the activity of the soft gelatin capsule of saquinavir in combination with ritonavir or nelfinavir and combinations of delavirdine, and/or adefovir dipivoxil in a group of subjects with indinavir experience and significant viral load levels.

仅限核心实验室-样品处理。 HIV蛋白酶抑制剂是一类新的抗逆转录病毒药物，具有很强的活性。茚地那韦，与齐多夫定和拉米夫定联合给齐多夫定经验丰富的患者，减少了约85%的患者的病毒载量低于500拷贝/毫升，长达一年。 这使得至少15%的患者尽管使用了含茚地那韦的联合方案，但病毒载量仍高于每毫升500拷贝。 对于病毒载量丰富或从未经历过病毒载量低于500拷贝/毫升的人，使用含茚地那韦的联合方案的最佳治疗方法尚不清楚。 本研究正式测试沙奎那韦软胶囊与利托那韦或奈非那韦以及地拉韦啶和/或阿德福韦酯的组合在具有茚地那韦经验和显著病毒载量水平的一组受试者中的活性。